Article
Alzheimer's drug slows progression of cognitive decline in clinical trial, drugmakers say | CNN
Rating:
0.0
Views:
61
Likes:
1
Library:
1
A monoclonal antibody treatment for Alzheimer's disease called lecanemab slows the progression of cognitive decline by 27% compared with a placebo, drugmakers Biogen and Eisai said Tuesday.
Rate This Post
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value